Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + Nab-paclitaxel + Cisplatin in ESCC
NCT02041819Phase 2Withdrawn
- Sponsor
- Zhejiang University
- Start
- Feb 2014
- Primary completion
- Jan 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang University. Primary endpoint: Response Rate at 2 months. Planned start Feb 2014; status: withdrawn.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02041819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041819.